Monoclonal antibody (mAb) product innovation aim of facility expansion in KansasAugust 23, 2024A $130-million investment through 2026 is expected to bolster production and development of monoclonal antibody-based therapy, including a potential product in canine dermatology.
SPONSORED CONTENTMore life to love for patients with certain types of canine CHF. See how different formulations help dog owners manage certain types of CHF in their pets. + Learn More